Friday, February 07, 2025 9:48:41 AM
From latest 10q and with $4mil in financing since... "The Company believes its working capital at September 30, 2024 will be sufficient to meet the business objectives as presently structured only through the fourth quarter of 2024. As such, there is substantial doubt that we can continue as a going concern beyond that date."...they burn thru $2.5-$3mil per quarter now b4 the trial starts...something gotta give...i'm not a hater by any means...imao..r
Recent OGEN News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 12:30:17 PM
- Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury • GlobeNewswire Inc. • 04/13/2026 12:30:00 PM
- Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation • GlobeNewswire Inc. • 03/25/2026 10:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/23/2026 04:15:07 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/19/2026 09:24:57 PM
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-K • GlobeNewswire Inc. • 03/17/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 08:30:41 PM
- ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION • GlobeNewswire Inc. • 03/12/2026 12:30:00 PM
- ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION • GlobeNewswire Inc. • 03/11/2026 12:30:00 PM
- Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia • GlobeNewswire Inc. • 03/10/2026 12:30:00 PM
- Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy • GlobeNewswire Inc. • 02/09/2026 01:30:00 PM
- Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care • GlobeNewswire Inc. • 02/02/2026 01:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/22/2026 09:11:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2026 09:05:42 PM
- Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/14/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:55:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:49:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:38:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:25:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:19:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 09:05:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/12/2025 11:28:44 PM
- Oragenics Q3 2025 Shareholder Update • Business Wire • 11/12/2025 01:30:00 PM
